5:52 PM
 | 
Sep 28, 2015
 |  BC Extra  |  Clinical News

Verastem halts mesothelioma trial

Verastem Inc. (NASDAQ:VSTM) fell $3.82 (67%) to $1.85 on Monday after it halted enrollment of the Phase II COMMAND study of defactinib ( VS-6063) to treat mesothelioma due to futility. A DSMB found no difference in progression-free survival between defactinib and placebo in a pre-planned interim analysis, in both the intent-to-treat...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >